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Objective: The prospective SONATA pivotal Investigational Device Exemption (IDE) trial
was performed in the United States (US) and Mexico to examine the safety and effectiveness
of transcervical ﬁbroid ablation (TFA) in the treatment of symptomatic uterine ﬁbroids. This
is an analysis of 12-month clinical outcomes in the US cohort.
Methods: TFA with the Sonata® System was performed on women with symptomatic
uterine ﬁbroids. The 12-month co-primary endpoints were reduction in menstrual blood
loss and freedom from surgical reintervention. Symptom severity, quality of life, patient
satisfaction, safety, and reductions in uterine and ﬁbroid volumes were also evaluated.
Results: One hundred twenty-ﬁve patients were enrolled and treated in the US. Both coprimary endpoints were achieved in this US-based cohort, as 65.3% of patients reported
≥50% reduction in menstrual bleeding and 99.2% of patients were free from surgical
reintervention. Symptom improvement was noted by 97.4% of patients and 98.3% were
satisﬁed. Ninety-ﬁve percent of patients reported reduced menstrual bleeding at 12 months,
and 86.8% noted >20% reduction. Signiﬁcant mean improvements at 12 months were
realized in both symptom severity and health-related quality of life (33.8 points and 45.8
points, respectively; all P<0.0001). Mean maximal ﬁbroid volume reduction per patient was
63.8%. There was a 0% incidence of device related adverse events. Mean length of stay was
2.5 hrs and 50% of patients returned to normal activity within 1 day.
Conclusion: This analysis of US patients in the SONATA pivotal IDE trial demonstrates
results consistent with those in the full cohort. TFA with Sonata signiﬁcantly reduced ﬁbroid
symptoms with a low surgical reintervention rate through 12 months. These results support
the efﬁcacy and safety of the Sonata system as a ﬁrst-line treatment for women affected by
symptomatic uterine ﬁbroids.
Keywords: uterine leiomyoma, transcervical ﬁbroid ablation; TFA, radiofrequency ablation,
Sonata system
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The SONATA pivotal IDE trial (“SONATA trial;” ClinicalTrials.gov Identiﬁer
NCT02228174) was a prospective, longitudinal, multicenter, single-arm trial of
transcervical ﬁbroid ablation (TFA) with the Sonata® system in a cohort of
women with symptomatic uterine ﬁbroids.1 The primary endpoints at 12 months
have been reported, and follow up is ongoing through 36 months. The overall trial
population of 147 women were made up of patients from the US (n=125) and
Mexico (n=22). Previous clinical results with the Sonata system demonstrated
International Journal of Women's Health 2019:11 387–394

387

© 2019 Hudgens et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.
php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the
work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For
permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

International Journal of Women's Health downloaded from https://www.dovepress.com/ by 98.142.115.124 on 07-Aug-2019
For personal use only.

Hudgens et al

signiﬁcant improvements in menstrual bleeding, quality of
life and overall symptom severity in conjunction with
excellent safety and surgical reintervention; total ﬁbroid
volume was reduced by 62%-67% at 12 months.1,2 This
analysis examines the 12-month clinical outcomes of TFA
with the Sonata system in the US patient cohort from the
full SONATA trial.

Materials and methods
The Sonata system (Gynesonics, Inc; Redwood City, CA,
USA), which has received United States Food and Drug
Administration (FDA) clearance and Conformité
Européene (CE) Mark, has been described in detail.2–5
Previously known as VizAblate™, the Sonata system
(Figure 1) consists of a custom RF generator, a laptopbased ultrasound system with custom Graphical Guidance
Software (GGS), and a single-use Radiofrequency
Ablation (RFA) Handpiece integrally combined with a
reusable Intrauterine Ultrasound (IUUS) Probe in a single
treatment device. This system provides the gynecologist
with a real-time, image-guided transcervical treatment
option. Therapeutic radiofrequency energy is delivered to
the ﬁbroid according to a treatment cycle that is dependent
on ablation size. Each ablation is scalable and determined
graphically by the treating physician, maximizing the percentage of each ﬁbroid to be ablated while avoiding thermal injury to adjacent viscera. The anesthesia choice for
each patient may be individualized, as there is no requirement for general anesthesia; conscious sedation, and regional anesthesia (all with or without adjuvant paracervical
blockade) were options provided within the SONATA
clinical trial.
Premenopausal women between ages 25–50 with
symptomatic uterine ﬁbroids associated with heavy

Figure 1 The Sonata treatment device, combining an intrauterine sonography
probe with a radiofrequency ablation handpiece into a single integrated handpiece.
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menstrual bleeding were eligible for the SONATA trial if
they had up to 10 myomata of International Federation of
Gynecology and Obstetrics (FIGO) types 1, 2, 3, 4, and/or
2-5 (transmural) between 1–5 cm in diameter, experienced
heavy menstrual bleeding as documented by a pictorial
blood loss assessment chart (PBAC) score between 150–
500, and had at least one ﬁbroid that either indented
(FIGO types 1, 2, 2-5) or abutted (FIGO type 3) the
endometrial cavity. While type 5 and type 6 subserous
myomata did not count towards the total number of
ﬁbroids, they could be ablated at the discretion of the
investigator. Women were excluded if they desired fertility, had type 0 ﬁbroids 1 cm or larger, had multiple
endometrial polyps or any polyps ≥1.5 cm in diameter, a
history of endometrial or ﬁbroid ablation, prior uterine
artery embolization (UAE), current tubal implants and
clinically signiﬁcant adenomyosis or substantial ﬁbroid
calciﬁcation.
Patients underwent screening that included transvaginal sonography, contrast-enhanced magnetic resonance
(MR) imaging, assessment of menstrual bleeding via a
pictorial blood loss assessment chart (PBAC), symptomatology and quality of life evaluation using the Uterine
Fibroid Symptom and Quality-of-Life (UFS-QoL)
Questionnaire, and a recording of baseline general health
status using the EQ-5D (EuroQoL) questionnaire. All
patients underwent cervical cancer and endometrial hyperplasia/carcinoma screening.
The US FDA approved the SONATA Investigational
Device Exemption (IDE) trial in the US. Approvals were
obtained from local and central institutional review boards
(Table S1) prior to patient enrollment. The research was
conducted according to the principles stated in the World
Medical Association Declaration of Helsinki. Each patient
provided her written informed consent to participate in the
trial. All studies and records had protected health information deidentiﬁed.
The two co-primary endpoints of the SONATA trial, as
required by the FDA, consisted of menstrual bleeding
reduction at 12 months and freedom from surgical reintervention due to heavy menstrual bleeding (HMB) through
12 months. Overall study success required meeting the
individual success criteria for both co-primary endpoints.
Each patient was considered to have had a successful
treatment outcome if she experienced ≥50% reduction in
PBAC score with the score being <250. In terms of study
success for this endpoint, the lower conﬁdence limit (LCL)
of the percentage of patient success was ≥45%. For the
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surgical reintervention co-primary endpoint, patient success was deﬁned as a lack of surgical reintervention for
HMB due to treatment failure at 12 months, and its study
success criterion was a LCL of the percentage of patient
success ≥75%.
Secondary endpoints included patient safety, reduction
in total and perfused ﬁbroid volumes at 12 months, change
in the symptom severity score (SSS) and health-related
quality of life (HRQOL) subscales of the UFS-QOL
Questionnaire, overall patient treatment outcome using
the Overall Treatment Effect (OTE) questionnaire, time
to return to normal activity, patient satisfaction, change
in general health outcome as determined by the EQ-5D
questionnaire, pain and tolerance of the procedure, mean
length of stay (LOS) and occurrence of pregnancy with
pregnancy outcome. Treated patients were followed at
10 days, 30 days, 3 months, 6 months and at 12 months,
with longer-term follow-up planned for 24 months and
36 months.
All statistical analyses were performed with SAS 9.3
(SAS, Cary, NC). Values were considered signiﬁcant at the
level of α=0.05.

Table 1 Baseline Patient Characteristics
Characteristic

Results

Age1, N
Mean ± SD

125
43.5 ± 4.0

Median

44.0

Min, Max

33, 50

Ethnicity, N
Hispanic or Latino

125
21 (16.8%)

Not Hispanic or Latino

104 (83.2%)

Race2, N

125

American Indian or Alaska Native

3 (2.4%)

Asian
Black or African American

2 (1.6%)
49 (39.2%)

Native Hawaiian or Other Paciﬁc

1 (0.8%)

Islander
White

60 (48.0%)

Other

11 (8.8%)

BMI, N3

125

Mean ± SD

29.5 ± 6.4

Median
Min, Max

28.0
18.0, 49.8

Notes: 1Age in years. 2Subjects indicating multiple races are counted once under
each race. Percentages may add to more than 100%. 3Calculated for those with
both height and weight measurements (kg/m2)

Results
Twenty-one clinical study sites in the US enrolled and
treated 125 patients. Baseline patient and ﬁbroid characteristics are provided in Table 1 and Table 2, respectively.
Mean age of enrolled patients was 43.4±4.0 years with a
mean body mass index (BMI) of 29.5±6.4 (kg/m2).
Patients were 48% White, 39% Black, and 17% Latina
(Table 1).
Three patients were excluded from the Full Analysis Set
population as they were diagnosed with menopause during
the 12 months after TFA with the Sonata system, with a
resultant inability to provide a PBAC diary at their 12month visits. Thus, the Full Analysis Set consists of 122
patients of the 125 patients. For the menstrual bleeding
reduction endpoint, 121 of the 122 patients were included
in this analysis, as one patient who underwent surgical
reintervention prior to her 12-month visit was excluded
from the analysis of this endpoint per the study statistical
analysis plan. For the surgical reintervention endpoint evaluation, all 122 patients in the Full Analysis Set were
included.
All 125 patients were treated in an outpatient setting,
including 7 physician practice ofﬁces and 4 ambulatory
care centers. Sixty-nine patients (55.2%) were treated in an
operating room, 33 (26.4%) received their procedures in
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Table 2 Baseline PBAC and Fibroid Characteristics, Full Analysis
Set (N=122)
Characteristic

Results

PBAC, N

122

Mean ± SD
Median

293.5 ± 96.1
281.0

Min, Max

150.2, 498.3

Total Fibroid Volume (cc), N

117

Mean ± SD

72.3 ± 90.1

Median
Min, Max

38.9
0.8, 522.9

Total Uterine Volume (cc), N
Mean ± SD

122
272.9 ± 155.8

Median

234.4

Min, Max

80.7, 868.1

an ambulatory care center while 23 (18.4%) patients were
treated in a physician ofﬁce. Seventy-four patients (59.2%)
received general anesthesia while 51 (40.8%) had their
procedures under conscious sedation. Paracervical blockade was co-administered as an ancillary local anesthetic
modality in 54 (43.2%) of patients. Mean length of stay
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Table 3 Change in PBAC Score by Visit
PBAC Score

Baseline

3 Monthsa

Change

% Change

N
Mean ± SD

121
293.9± 96.3

117
175.9 ± 110.3

117
-119.3 ± 116.0

117
-38.9 ± 39.1

Median

283.6

153.4

-113.0

-44.4

Min, Max
P

150.2, 498.3

11.7, 647.8

-395.2, 445.1
<.0001

-96.5, 219.6
<.0001

6 Months

Abs. Change

% Change

N

121

121

121

Mean ± SD
Median

146.3 ± 102.7
114.9

-147.6 ± 105.7
-133.5

-50.0 ± 30.2
-56.1

Min, Max

11.7, 519.9

-469.5, 124.9

-94.8, 38.3

<.0001

<.0001

P
12 Months

Abs. Change

% Change

N
Mean ± SD

121
141.3 ± 107.2

121
-152.6 ± 125.0

121
-50.2 ± 42.4

Median

130.7

-145.2

-58.1

Min, Max
P

0.0, 902.2

-491.9, 679.4
<.0001

-100.0, 304.9
<.0001

(including procedure time) was 2.5±1.3 hrs, with 91 of 125
patients (72.8%) having a length of stay ≤3 hrs. Median
length of stay was 2.3 hrs.
Nearly all patients (95%; 115/121) experienced some
reduction in menstrual bleeding at 12 months after TFA,
with 86.3% experiencing reduced menstrual bleeding by
3 months. Regarding the 12-month PBAC timepoint,
65.3% (79/121) of patients (95% CI 56.1–73.7%) reported
at least 50% reduction in menstrual bleeding, which met
the endpoint success criterion that the LCL of the 95% CI
be ≥45%. Detailed PBAC reduction results are provided in
Table 3.
The other co-primary endpoint, surgical reintervention
for heavy menstrual bleeding at 12 months post-ablation,
was also met. Only one patient underwent surgical intervention (elective hysterectomy for abnormal uterine bleeding) within the ﬁrst 12 months of her post-treatment
course. Thus, 99.2% (95% CI 94.3–99.9%) of patients
were free from surgical reintervention for heavy menstrual
bleeding at 12 months after treatment with the Sonata
system. This outcome met the endpoint success criterion
that the LCL of the 95% CI be ≥75%. The percentage of
patients achieving either co-primary endpoint did not signiﬁcantly vary by ethnicity and were similar for White,
Black and Latina patients.
Treatment with the Sonata system resulted in signiﬁcant
improvements in all patient-reported outcomes, beginning
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with the 3-month visit (the ﬁrst post-treatment visit that
included these questionnaires). As seen in Figure 2, patients
reported a mean SSS reduction of 33.8 points (N=115) at
12 months post-procedure (P<0.0001) and a mean increase
of 45.8 points in HRQOL (N=115; P<0.0001). Regarding
the OTE questionnaire, 97.4% of patients responding at
12 months (112/115) noted improvement in their ﬁbroid
symptoms, while 1.7% (2/115) reported no change in symptoms and 0.9% (1/115) noted a worsening of symptoms.
Patients reported signiﬁcantly improved health status
on the EQ-5D questionnaire at 12 months post-procedure.
Self-reported scores on the EQ-5D questionnaire range
from values of less than 0, representing health states
worse than “death”, to a maximum score of 1.0, representing “perfect health.” At baseline, US patients in the
SONATA trial had a mean overall health score of 0.73
(N=122). At 12 months (N=114), their mean EQ-5D score
rose to 0.90 (P<0.0001). Of note, health status signiﬁcantly improved as early as 3 months after treatment
with Sonata, with EQ-5D scores rose to 0.88 at 3 months
(n=118; P<0.0001).
Of 115 patients reporting at 12 months, 98.3% of
patients expressed satisfaction with their treatment, and
a similar percentage (96.5%) would also recommend
Sonata to a friend or family member. Speciﬁcally,
70.4% of reporting patients indicated that they were
“very satisﬁed” with treatment, 18.3% were “moderately
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SSS

HRQOL

100
90
80

86.7

86.2

80
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70
60
50
40

54.3
40.6

30

24.8

20

20.3

10
0

Baseline (n=122, 122) 3 months (n=120, 119) 6 months (n=118, 117) 12 months (n=115, 115)

Figure 2 Improvements in uterine ﬁbroid symptom and quality of life questionnaire subscales through 12 months in the FAS population (mean values). The SSS subscale
demonstrates symptom reduction whereas the HRQoL subscale denotes increases in health-related quality of life. The results on both subscales signify improvement (all
P<0.0001).

satisﬁed,” 9.6% were “somewhat satisﬁed,” 0.9% were
“somewhat dissatisﬁed,” and 0.9% were “moderately
dissatisﬁed” at 12 months. No patients were “very dissatisﬁed” with their treatment. Similarly, 82.6% (95/115)
would “deﬁnitely recommend” treatment with Sonata,
13.9% would “probably recommend” it, and 3.5%
would “probably not recommend” it at 12 months. No
patient indicated that she would “deﬁnitely not recommend” the treatment.
Pain scores were evaluated on a scale from 0 (“No pain
sensation”) to 10 (“Most intense pain imaginable”). Mean
procedural pain scores were 0.01±0.1 for procedures under
general anesthesia (N=74) and 0.6±1.6 for procedures performed under conscious sedation (N=51). Recovery pain
scores were 3.4±2.9 for patients receiving general anesthesia and 2.5±2.7 for those who were treated under conscious
sedation. Overall, 98% (122/125) of patients found treatment with the Sonata system to have been tolerable.
Speciﬁcally, 63.2% (79/125) of patients reported the procedure to have been “Very Tolerable”, 32% (40/147) found the
procedure to be “Moderately Tolerable”, 2.4% (3/147) characterized it as “Minimally Tolerable”, and 2.4% (3/147)
said it was “Intolerable”. Overall mean pain scores regardless of anesthesia choice were 0.2±1.0 (range 0.0–7.0) during the procedure and 3.0±2.8 (range 0.0–10.0) during
recovery (reported from the time between procedure completion and discharge).
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Table 4 Attributes of Ablated Fibroids*
Procedure Parameter
Treated Fibroid Diameter, N
<1 cm

392
20 (5.1%)

1 – 2 cm

144 (36.7%)

>2 – 3 cm
>3 – 4 cm

108 (27.6%)
69 (17.6%)

>4 cm

51 (13.0%)

Treated Fibroid Type, N
Type 1

392
13 (3.3%)

Type 2

76 (19.4%)

Type 2-5
Type 3

70 (17.9%)
102 (26.0%)

Type 4

89 (22.7%)

Type 5
Type 6

39 (9.9%)
3 (0.8%)

Number of Fibroids/Patient, N

125

Mean±SD
Median

3.6 ± 2.2
3.0

Min, Max

1.0, 10.0

Number of Treated Fibroids/Patient, N
Mean±SD

125
3.1 ± 2.2

Median

3.0

Min, Max
Treated Fibroid Diameter (cm), N

1.0, 9.0
392

Mean±SD

2.5 ± 1.2

Median
Min, Max

2.3
0.3, 6.5

Notes: *Determined via intrauterine sonography at the time of treatment
SD, standard deviation;
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Table 4 summarizes characteristics of ablated ﬁbroids.
The mean maximal reduction in total leiomyoma volume
per patient from baseline to 12 months was 63.8%
(N=109). Of the 121 patients included in the analysis of
the bleeding reduction co-primary endpoint, there were 33
patients (27.3%) for whom a type 3 myoma was the sole
qualifying ﬁbroid type (ie, they did not have an indenting
ﬁbroid such as a type 2 myoma). Of these 33 patients, 22
(66.7%) had at least a 50% reduction in PBAC score at
12 months. This is similar to the percentages of patients
with indenting ﬁbroids who achieved a 50% or greater
reduction in PBAC score at 12 months (58.3%, 67.4%
and 63.0% for patients with at least one type 1 ﬁbroid,
patients without any type 1 ﬁbroids and at least one type 2
ﬁbroid, and patients without any type 1 and type 2 ﬁbroids
and at least one type 2-5 ﬁbroid, respectively).
Patients reported returning to normal daily activities in 2.1
±2.3 days, and half of the patients returned to normal activity
the day following the procedure. Patients with employment at
the time of procedure indicated having returned to work 3.7
±2.6 days post-procedure on average, with half of the patients
returning to work within 3 days after the procedure. Patients
resumed a normal diet at 0.7±1.3 days, normal sleep at 0.8
±1.7 days, and normal urinary and bowel functions at 0.2
±0.7 days and 1.5±1.9 days, respectively.
There were no occurrences (0.0%) of device related
adverse events, serious or otherwise. There was 1 procedure-related serious adverse events reported in a single
subject (0.8%). That single procedure-related serious
adverse event involved a deep venous lower extremity
thrombus diagnosed 15 days post-procedure, managed as
an outpatient without sequelae.
As shown in Table 5, the results of the US cohort from
the SONATA trial and that of the original cohort including
patients from Mexico are provided.

Discussion
TFA with the Sonata system provides a safe and effective
transcervical treatment for symptomatic uterine ﬁbroids
that uses RF ablation to treat all types of nonpedunculated
ﬁbroids.5 Because it contains an integral intrauterine sonography probe, Sonata can image, target and treat ﬁbroids
that are not accessible to other transcervical methods such
as hysteroscopic morcellation or resectoscopy. Indeed, in
the SONATA clinical trial, 77.3% of treated ﬁbroids in the
US cohort were not amenable to operative hysteroscopy,
including intramural, transmural and subserous myomata.
While it is true that some type 1 and type 2 submucous
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Table 5 Outcomes of the Full and US-only Cohorts of the
SONATA Pivotal IDE Trial
Parameter

SONATA

SONATA

(US+Mexico)

(US)

≥ 50% reduction in menstrual

64.8 (N=142)

65.3 (N=121)

bleeding at 12 months (%)
Freedom from surgical reinter-

99.3 (N=143)

99.2 (N=122)

Mean SSS reduction at 12
months (points)

32.1 (N=135)

33.8 (N=115)

Mean HRQOL increase at 12

43.7 (N=134)

45.8 (N=115)

months (points)
Percentage of patients reporting

96.3 (N=135)

97.4 (N=115)

2.2 (N=139)

2.1 (N=118)

vention at 12 months (%)

improvement in overall ﬁbroid
symptoms (OTE questionnaire)
Mean return to normal daily
activities (days)
Mean return to work (days)

3.6 (N=111)

3.7 (N=96)

Mean length of stay (hours)

2.5 (N=147)

2.5 (N=125)

Percentage of patients at least
“Somewhat Satisﬁed” at 12

97.1 (N=135)

98.3 (N=115)

97.1 (N=135)

96.5 (N=115)

months
Percentage of patients who
would at least “Probably
Recommend” Sonata to a friend
or family member

myomata can be resected hysteroscopically, TFA obviates
the inconvenience involved in removal of the resultant
ﬁbroid fragments, can address larger and deeper submucous ﬁbroids that are less amenable to resection, and can
be used in the same session to ablate other nonresectable
ﬁbroids without the need to also employ a resectoscope.
The US cohort represents 85% of patients treated in the
SONATA trial, as 22 patients (15%) in the 147-patient
SONATA pivotal IDE trial were enrolled in Mexico.
Clinical outcomes for US patients in the SONATA trial
were consistent with those in the full (US+Mexico)
SONATA trial population. The US cohort results also
met both co-primary endpoints of the clinical trial.
Results from this US cohort of the SONATA trial as
well as those from the full trial are consistent with the
results of the previous FAST-EU trial, in which 64.6% of
patients (31/48) experienced a >50% reduction in menstrual bleeding and reported a mean reduction of 35.3
points in their SSS, both at 12 months.1,3 In both the full
and US-only cohorts of the SONATA trial, 95% of
patients had bleeding reduction, with 86.3% of patients
experiencing bleeding reduction by 3 months. In the
overall SONATA cohort of 147 patients, there were two
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reported procedure-related serious adverse events, one in
Mexico and one in the US. There were no device related
adverse events, serious or otherwise in the full SONATA
or US cohorts. Patient satisfaction was similar in both
groups.
The SONATA clinical trial was noteworthy for its inclusion of a wide variety of ﬁbroid types (every FIGO ﬁbroid
type other than pedunculated ﬁbroids [types 0 and 7] are
treatable by the Sonata system) and increased number of
treatable ﬁbroids/patient compared with the prior FAST-EU
clinical trial in Europe and Mexico.2,3 The SONATA trial
included a robust patient selection process to minimize
confounding factors, excluding patients with other etiologies of abnormal uterine bleeding such as anovulation and
bleeding disorders. Furthermore, the study included a mix
of patient-reported outcomes to complement the objective
reintervention and bleeding primary endpoints.
Patients who expressly desired fertility were excluded.
This was secondary to ethical reasons as SONATA was a
pivotal safety and effectiveness investigational study.
Nonetheless, the SONATA trial includes 3-year follow up
of patients and the reporting of any pregnancy outcomes
should they occur.

Conclusion
This analysis of US patients in the SONATA pivotal IDE
trial demonstrates results consistent with those in the full
cohort. TFA with Sonata signiﬁcantly reduced ﬁbroid
symptoms with a low surgical reintervention rate through
12 months. These results support the efﬁcacy and safety of
the Sonata system as a ﬁrst-line treatment for women
affected by symptomatic uterine ﬁbroids.
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